GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Profiles / Miguel Viveiros
  • +351 213 652 600
  • +351 213 632 105
  • Send Mail
  • Download CV
  • Orcid
  • NOVA Research

Miguel Viveiros

Full Professor

GHTM Scientific Coordinator

GHTM Group: TB, HIV and opportunistic diseases and pathogens, THOP PhD members

ProfileResearchTop 5 Publications

Full Professor in Biomedical Sciences/Medical Microbiology and Vice-Director of the Institute of Hygiene and Tropical Medicine of the New University of Lisbon. Professor in Biomedical Sciences, Medical Microbiology, International Health and Tropical Medicine. Expert on the early diagnosis of active or latent TB, mycobacteriology and new therapeutics for MDRTB and XDRTB. Devoted to the study and development of new diagnostic tools and alternative therapies to treat drug resistant infectious diseases such as multidrug resistant tuberculosis and methicillin-vancomycin resistant staphylococcal infections.

Scientific Coordinator of the Foundation of Science and Technology Research Center – Global Health and Tropical Medicine (UID/04413/2020) since 2020 (https://ghtm.ihmt.unl.pt/ ).  Founding member and currently management committee member of the Study Group for Mycobacterial Infections (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (https://www.escmid.org/index.php?id=897 ). General Director and Scientific Coordinator of the “Ciência LP – International Center for Advanced Training in Fundamental Sciences for Scientists from Portuguese-speaking Countries” (UNESCO Category 2 Center) (https://www.ciencialp.pt/centro-ciencia-lp/ ) and Vice-President of the Portuguese Society for Microbiology (https://spmicrobiologia.wordpress.com/orgaos-sociais/ ). Vice-Chair (2017) and Chair (2019) of the Gordon Research Conference – Multi-Drug Efflux Systems –  https://www.grc.org/multi-drug-efflux-systems-conference/2019/ ). Member of the evaluation panel of Fundação para a Ciência e a Tecnologia of Portugal and expert Evaluator for the MRC South Africa and UK (area Tuberculosis), Wellcome Trust Awards, The Research Foundation – Flanders (FWO), Belgium, Dutch Research Council (NWO), Holland, Haut Conseil de l’Évaluation de la Recherche et de l’Enseignement Supérieur (HCERES) and National Agency for Scientific Evaluation (ANEP), Spain.

Author/co-author of over 200 scientific papers in peer review national and international journals, books and book-chapters in mycobacteriology, tuberculosis, bacteriology, resistance to antibiotics, microbial genetics, molecular epidemiology and immunology. Supervised and/or co-supervised 5 pos-docs, 9 PhD, 30 MSc students.

https://www.cienciavitae.pt/DF17-B4BF-8756

 

Expert in the early diagnosis of active or latent TB and new therapeutics for MDRTB and XDRTB. Devoted to the study and development of new diagnostic tools and alternative therapies to treat drug resistant diseases such as multidrug resistant tuberculosis and methicillin-vancomycin resistant staphylococcal infections, using new biotechnologies and new therapies incorporating non-antibiotic adjuvants of chemotherapy.

Studied, in the last 15 years, the contribution of the efflux-pumps and membrane transporters to bacterial multidrug resistant phenotypes and how we can prevent, reverse or reduce the level of resistance and recover the effectiveness of the antibiotics to which the bacteria became resistant. With an international team of collaborators, documented the mutations in drug targets and the corresponding associated minimal inhibitory concentrations for the majority of the anti-TB drug targets in M. tuberculosis and well as the effectiveness of various new inhibitors on many of the MDR bacteria in particular M/XDRTB. Conducted the laboratory diagnosis and the characterization of the determinants for resistance by phenotypic and genotypic assays, using new technical approaches such as Whole genome sequencing and real-time phenotypic assays. These studies also demonstrated the public health implications associated with these findings and contributed to the improvement of the currently recommended first and second line multi-drug anti-TB treatments.

Involved in the design and conduction of several multicenter studies in the field of mycobacteriology and laboratory diagnosis of tuberculosis involving, Becton & Dickinson, EUCAST, ESGMYC and TB Alliance, and pharmaceutical companies like Janssen, Otsuka and Tecnimede. Participated in the validation of the SIRE KIT Nitratase for M. tuberculosis DST with the Brazilian TB lab-network. Deeply involved in the development of TB nanodiagnostics in collaboration with the Nanotheranostics Group FCT/UNL (PI- Pedro V. Baptista) and the Biotech Company Nano4Global (https://nano4global.com/website/ ).

SDG3SDG4SDG5SDG17

  1. Patil M, Munteanu T, Brasseur G, Ferreira C, Costa SS, Couto I, Athar M, Asunis E, Vargiu AV, Viveiros M, DiGiorgio C, Brunel F, Raimundo JM, Camplo M, Siri O, Bolla JM. Unlocking the Gates: A Novel Diagnostic Molecule for Quantifying Efflux Levels in Gram-Positive Bacteria. Adv Healthc Mater. 2025 Apr;14(11):e2404145. doi: 10.1002/adhm.202404145.
  2. Elias R, Modesto A, Machado D, Pereira B, Phelan J, Melo-Cristino J, Lito L, Gonçalves L, Portugal I, Viveiros M, Campino S, Clark TG, Duarte A, Perdigão J. Dissemination of arr-2 and arr-3 is associated with class 1 integrons in Klebsiella pneumoniae clinical isolates from Portugal. Med Microbiol Immunol. 2025 Jan 8;214(1):6. doi: 10.1007/s00430-024-00814-y.
  3. Ferrinho P, Viveiros M, Fronteira I. Antimicrobial resistance, society and environment: A glocal syndemic. One Health. 2023 Feb 17;16:100512. doi: 10.1016/j.onehlt.2023.100512.
  4. Antimycobacterial Susceptibility Testing Group. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. Eur Respir J. 2022 Apr 14;59(4):2200166. doi: 10.1183/13993003.00166-2022.
  5. Bateson A, Ortiz Canseco J, McHugh TD, Witney AA, Feuerriegel S, Merker M, Kohl TA, Utpatel C, Niemann S, Andres S, Kranzer K, Maurer FP, Ghodousi A, Borroni E, Cirillo DM, Wijkander M, Toro JC, Groenheit R, Werngren J, Machado D, Viveiros M, Warren RM, Sirgel F, Dippenaar A, Köser CU, Sun E, Timm J. Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. J Antimicrob Chemother. 2022 Mar 9:dkac070. doi: 10.1093/jac/dkac070.

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

 

Loading Comments...
 

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok